国产亚洲一区二区自拍视频-被灌满白浆的人妻视频-亚洲激情av一区二区三区-欧美+日本+国产+在线a∨观看

首頁(yè) > 產(chǎn)品目錄 > 信號(hào)通路 > JAK/STAT 信號(hào)通路 > JAK > 菲卓替尼

菲卓替尼

ChemLeader 98+%

Fedratinib | TG-101348 | SAR 302503

產(chǎn)品編號(hào):CL1888 CAS No.:936091-26-8 MDLNo: 分子式:C27H36N6O3S 分子量:524.68
規(guī)格 庫(kù)存 目錄價(jià) 會(huì)員專享價(jià) 數(shù)量

暫無(wú)牌價(jià)信息,您可以發(fā)送詢價(jià),我們會(huì)盡快給你回復(fù)。

化學(xué)品安全說(shuō)明書(MSDS)

下載MSDS
  • 基本信息
  • 相關(guān)文檔
  • 產(chǎn)品詳情
  • 相關(guān)文獻(xiàn)
基本信息
英文名稱 Fedratinib | TG-101348 | SAR 302503
中文名稱菲卓替尼
CAS號(hào)936091-26-8
分子式C27H36N6O3S
分子量524.68
外觀White to light yellow powder
儲(chǔ)存條件Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).
產(chǎn)品詳情

 Fedratinib, also known as TG101348 and SAR302503, is a JAK2 inhibitor, is also an orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. JAK2 inhibitor TG101348 competes with JAK2 as well as the mutated form AK2V617F for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and the induction of tumor cell apoptosis. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs); the mutated form JAK2V617F has a valine-to-phenylalanine modification at position 617 and plays a key role in tumor cell proliferation and survival.

相關(guān)文獻(xiàn)
抱歉,暫時(shí)沒(méi)有相關(guān)文獻(xiàn)
相關(guān)產(chǎn)品
抱歉,暫時(shí)沒(méi)有相關(guān)產(chǎn)品
在線客服
小德
021-58180488
小立
021-58180488
在線服務(wù)時(shí)間: 工作日 9:00-18:00